NEW YORK – Becton Dickinson announced on Friday that it has received the CE mark for an expanded clinical application of a test assess immune function in patients with COVID-19.
The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes can now be marketed in Europe to identify and enumerate T-cell subtypes in COVID-19 patients.